BNP Paribas Asset Management
DNTH icon

BNP Paribas Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

BNP Paribas Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.7K Buy
582
+292
+101% +$25.5K ﹤0.01% 1729
2026
Q1 		$24.3K Buy
290
+74
+34% +$4.29K ﹤0.01% 1971
2025
Q4 		$9K Buy
+216
New +$8.37K ﹤0.01% 2164

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BNP Paribas Asset Management's DNTH Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Dianthus Therapeutics (DNTH) stake by 101% in Q2 2026, buying an estimated $25.5K and bringing the position to 582 shares worth $56.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1729.

BNP Paribas Asset Management first reported a position in DNTH in Q4 2025 and has held it in 3 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • BNP Paribas Asset Management held 582 shares of Dianthus Therapeutics worth $56.7K as of Q2 2026.
  • BNP Paribas Asset Management bought 292 Dianthus Therapeutics shares in Q2 2026, an estimated $25.5K.
  • Dianthus Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1729 holding.
  • BNP Paribas Asset Management first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.